1	Role of human challenge trials (HCTs) in drug development for respiratory syncytial virus
2	(RSV)
3	Procentiit Kundu PhD <sup>1</sup> Mark Quinn MPH <sup>2</sup> Jarad C. Christenson PhD <sup>1</sup> Elaine Thomas PhD <sup>2</sup>
4 5	Sima S. Toussi, MD <sup>3</sup> , Negar Niki Alami, MD <sup>3</sup> , Anindita Banerjee, PhD <sup>1*</sup>
6	<sup>1</sup> Pfizer Inc., Cambridge, MA, USA
7	<sup>2</sup> USA Pfizer Ltd, London, UK
8	<sup>3</sup> Pfizer Inc., New York, NY
9 10	
11	
12	Abstract
13	Human challenge trials (HCTs) are powerful in establishing early proof-of-concept for
14	experimental drugs and understanding disease pathogenesis. In this study, we conducted a
15	comprehensive assessment of HCTs to understand the viral load dynamics and symptom score
16	kinetics of respiratory syncytial virus (RSV) to facilitate drug development for RSV. We estimated
17	viral load (VL) and symptom related measures in placebo and relative reduction (RR) of the
18	measures in the experimental drug using a systematic search on double-blind, placebo-controlled
20 19	mean neak VI and time to mean neak total symptom score (TSS) where descriptive statistics were
21	summarized. Number of studies varied across measures, from 4 (151 subjects in total) to 7 (247
22	subjects in total). Overall, treatment reductions of 54% (95% CI: $32\% - 76\%$ , $I^2 = 91\%$ ) and 76%
23	$(95\%$ CI: $68\% - 85\%$ , $I^2 = 19\%$ ) are observed in mean VL area under curve (AUC) and mean TSS
24	AUC, respectively. In placebo, mean time to mean peak VL/TSS was 6.99/7.09 days (95% CI:
25	6.24/6.06 - 7.74/8.12 days). In comparison to other viruses in HCTs, peak VL occurs earlier for
26	influenza (1.7 days) and at similar time for SARS-nCoV-2 (7 days), whereas peak TSS occurs
27	earlier for influenza (2.9 days) and later for SARS-nCoV-2 (7.9 days). Our findings will inform
28 29	studies and understanding implications in clinical practice.
_	
30	
31	
32	
22	
პპ	
34	

35

37 <u>anindita.banerjee@pfizer.com</u>

<sup>36 \*</sup>Correspondence to: Anindita Banerjee, Pfizer Inc., 1 Portland St, Cambridge, MA-02139, US,

#### **Introduction:** 39

### 40

Respiratory Syncytial Virus (RSV) remains a major global health concern, particularly among 41 42 vulnerable populations, including infants, the elderly, and individuals with underlying medical 43 conditions<sup>1,2</sup>. In the United States and globally, RSV infection continues to cause severe 44 respiratory illnesses in high-risk populations, often requiring hospitalization and posing a 45 significant burden on healthcare systems<sup>3-7</sup>. In response to this ongoing public health challenge, 46 numerous randomized clinical trials have been conducted to assess the efficacy of various anti-47 viral treatments for RSV as a proof of mechanism. However, the landscape of RSV treatment is 48 complex and remains an unmet medical need, with a wide array of interventions being tested, and 49 outcomes that vary across studies.

50

51 Human challenge trials (HCTs), also known as controlled human infection studies, involve 52 intentionally exposing participants to a pathogen to test the effectiveness of treatments or 53 vaccines<sup>8</sup>. For drug development it is important to assess proof of mechanism and assess signal of 54 efficacy early in development. A human challenge model allows us to understand the effect of the 55 drug early during development and establish proof of mechanism.<sup>9</sup> By running these standard human challenge studies, it is feasible to gauge some sign of efficacy before running larger late 56 57 phase studies and de-risk later development. For RSV several companies have studied 58 investigational drugs using the available human challenge model.

59

60 In this manuscript, we provide the first comprehensive assessment of placebo measures and treatment efficacy reported in RSV human challenge studies. By conducting meta-analysis<sup>10,11</sup> a 61 62 widely popular statistical approach for combining studies, we seek to synthesize the available evidence, elucidate RSV VL kinetics and characterize the effectiveness of various interventions 63 64 for RSV based on data from the HCTs. The main objectives of this meta-analysis include summarizing the collective findings of RSV human challenge studies from published literature 65 66 or/and online clinical databases, identifying potential sources of heterogeneity across studies, such as patient populations, intervention types, and study designs, assessing overall placebo measures 67 and treatment responses for outcomes from human challenge studies. These outcomes include viral 68 69 load (VL) area under the curve (AUC), total symptom score (TSS) AUC, peak VL, time to peak 70 VL and time to peak TSS. The estimated overall measures in placebo from this meta-analysis 71 would inform the design of future RSV clinical trials. Further, we compare the placebo measures for some of the outcomes with those from published literature for influenza and SARS-nCoV-2<sup>12-</sup> 72 <sup>14</sup>, to understand the clinical profile of RSV.

- 73
- 74
- 75

#### 76 **Results:**

77

#### 78 **Study Characteristics**

79

Following the search strategy from PRISMA guidelines<sup>15</sup>, seven HCTs<sup>16-22</sup> were identified to be 80

81 included in the meta-analysis (Figure 1). The search started with a total of 428 RSV studies from

clinical databases and literature websites with key words "respiratory syncytial virus", "RSV", 82

83 "healthy volunteers", "healthy patients", "healthy cohort, "healthy participants", "healthy adults".

The search strategy was limited to English language papers only and publication from 1990 to 84

present, with any pharmaceutical product as the intervention. The websites ClinicalTrials.gov and 85 EudraCT were searched with the key words "respiratory syncytial virus", "RSV", "human 86 challenge", "viral challenge". Out of the 428 studies, 11 studies were from HCTs. We excluded 4 87 88 studies, one due to unavailability of data on the outcomes considered in our analyses, one due to 89 study design and objective (pre-exposure prophylaxis treatment) as our study aims at treatments 90 after inoculation to challenge virus, one due to assay used other than RT-qPCR as our study looked at VL measurements assessed from RT-qPCR assay and one due to vaccine as the investigational 91 92 treatment. The exclusion criterion led to 7 studies included in our analyses. These studies covered 93 7 different interventions in development, two of which are currently being evaluated in Phase 2 or 94 Phase 2/3 trials, EDP-938 and Sisunatovir (RV521), respectively. The study characteristics, 95 including demographics, are reported in Table 1. The number of subjects varied from 45 to 115 96 with a total of 544 subjects (including multiple cohorts from each studies), average age across the studies ranged from 23 to 28 years, proportion of females varied from 25 to 38% except for one 97 study from Johnson & Johnson<sup>21</sup> which recruited male subjects only, the year of recruitment 98 99 ranged from 2012 to 2018 and all were UK-based studies.

100

# 101 <u>Assessment of Risk of Bias</u>102

We reported the assessment of risk of bias for each of the HCT's in Supplementary Figure 1.
Overall, the biases are low for most of the domains as the studies are well-controlled, quarantine
and are run at a single site by the same vendor.

- 106 107
- 108 VL specific outcome measures

# 110 Mean placebo VL AUC

111

109

112 This analysis included 7 studies ranging in size from 12 to 30 participants, with a total of 128 113 participants. Individually, the placebo mean VL AUC dose varied from 432.80 to 790.20 114 log<sub>10</sub>PFUe.hr/mL (Figure 2). The I<sup>2</sup> statistic was used to assess the heterogeneity across studies 115 and was equal to 82% (p < 0.01) indicating considerable degree of heterogeneity (Figure 2). Under 116 a random effects model, the placebo mean VL AUC was 605.98 log<sub>10</sub>PFUe.hr/mL (95% CI: 491.60 117 - 720.37 log<sub>10</sub>PFUe.hr/mL) (Figure 2).

118

# 119 Relative reduction (RR) of mean VLAUC in treatment group compared to placebo

120

121This analysis involved 7 studies ranging in size from 20 to 55 participants and included a total of122247 participants. Individually, the RR of mean VL AUC in treatment group compared to placebo,123varied from 1% to 88% (Figure 3). The I² statistic was used to assess the heterogeneity across124studies and was equal to 91% (p < 0.01) indicating considerable degree heterogeneity (Figure 3).</td>125Under a random effects model, the RR of mean VL AUC was 54% (95% CI: 32% - 76%) compared126to placebo (Figure 3).

- 127128 *Mean placebo VL at peak*
- 129

This analysis included 7 studies ranging in size from 12 to 30 participants, with a total of 128 participants. Individually, the mean placebo VL at peak varied from 4.7 to 6.24 log<sub>10</sub>PFUe/mL

(Figure 4). The I<sup>2</sup> statistic was used to assess the heterogeneity across studies and was equal to
55% (p = 0.04) indicating a moderate degree of heterogeneity (Figure 4). Under a random effects
model, the mean placebo VL at peak was 5.38 log<sub>10</sub>PFUe/mL (95% CI: 4.94 – 5.81 log<sub>10</sub>PFUe/mL)
(Figure 4).

136

# 137 Time (in days) to mean placebo peak VL

138

139 Since most of the studies reported time to mean peak VL rather than mean time to peak VL for placebo subjects, we summarized the descriptive statistics for time to mean peak VL which are 140 141 evaluated assuming each study serves as a random subject. This analysis involved 6 studies ranging 142 in size from 12 to 30 participants, a total of 124 participants were included. Individually, the time 143 to mean placebo peak VL from inoculation ranged from 6.2 to 7.75 days. The mean and median time to mean placebo peak VL were 6.99 days (95% CI: 6.24 - 7.74 days) and 6.74 days (95% CI: 144 6.2 - 8 days), respectively. In comparison to other viral diseases, time to mean peak VL occurs 145 much earlier for influenza (~ 2 days)<sup>13,14</sup> and at a similar time in disease course for SARS-nCoV-146  $2 (\sim 7.3 \text{ days})^{12}$ . 147

148 149

## 150 Symptom specific outcome measures

151

153

# 152 Mean placebo total symptom score area under the curve (TSS AUC)

This analysis involved 4 studies ranging from 12 to 30 participants, 80 participants in total were included. Individually, the mean placebo TSS AUC varied from 269.40 to 606.90 (Supplementary Figure 2). The I<sup>2</sup> statistic was used to assess the heterogeneity across studies and was equal to 48% (p = 0.12) indicating a moderate degree of heterogeneity (Supplementary Figure 2). Under a random-effects model, the placebo mean TSS AUC was 404.96 (95% CI: 272.84 - 537.08) (Supplementary Figure 2).

160

### 161 *Relative Reduction (RR) of mean total symptom score area under the curve (TSS AUC)* 162

163 This analysis involved 4 studies ranging in size from 20 to 55 participants, a total of 151 164 participants were included. Individually, the RR of mean TSS AUC in the treatment group 165 compared to placebo varied from 29% to 82% (Figure 5). The I<sup>2</sup> statistic was used to assess the 166 heterogeneity across studies and was equal to 19% (p = 0.30) indicating low heterogeneity across 167 the studies (Figure 5). As a result, both common effect and random effects model produced the 168 same estimates of the RR of mean TSS AUC in the treatment group compared to placebo which 169 was 76% (95% CI: 68% - 85%) (Figure 5).

170

# 171 *Time (in days) to mean placebo peak total symptom score (TSS)*

172

We report the descriptive statistics as most of the studies reported time to mean peak TSS instead of mean time to peak TSS for placebo subjects. The statistics were evaluated in an analogous way to those described above for VL. This analysis involved 5 studies ranging from 12 to 30 participants, 107 participants in total were included. Individually, time to mean placebo peak TSS from inoculation varied from 6 to 8.04 days. The mean and median time to mean placebo peak TSS were 7.09 days (95% CI: 6.06 – 8.12 days) and 6.87 days (95% CI: 6 – 8.04 days) respectively.

In comparison to other viral diseases, peak TSS occurs earlier for influenza (~3 days)<sup>13,14</sup> and later
 in disease course for SARS-nCoV-2 (~9.4 days)<sup>12</sup>.

181

# 182 <u>Prediction Interval for a future HCT and Reference Interval for an individual recruited in a</u> 183 <u>future HCT</u>

184

185 We report the prediction interval and reference range for placebo VL AUC, placebo VL at peak 186 and placebo TSS AUC. From Supplementary Table 1, the 95% prediction interval for mean placebo VL AUC, mean placebo VL at peak and mean placebo TSS AUC in a future HCT are (218.97 -187 993.0 log<sub>10</sub>PFUe.hr/mL), (4.13 - 6.63 log<sub>10</sub>PFUe/mL) and (0 - 892.11), respectively. From 188 189 Supplementary Table 2, based on a frequentist approach, the 95% reference interval or the 190 "normal" range where 95% of the measurements from individuals recruited in a future HCT would lie are  $(0 - 1295.54 \log_{10} \text{PFUe.hr/mL})$ ,  $(1.58 - 9.18 \log_{10} \text{PFUe/mL})$  and (0 - 1288.25) for placebo 191 VL AUC, placebo VL at peak and placebo TSS AUC. We have also provided the plots including 192 193 prediction intervals at study-level and reference interval at an individual-level (Supplementary 194 Figure 3, Supplementary Figure 4, Supplementary Figure 5).

195

# 196197 Discussion:

198

199 We conducted the first of its kind systematic review and meta-analysis of RSV outcomes from 200 human challenge trials. We provided overall estimates for placebo group and relative reduction in 201 the treatment compared to placebo for the key measures including amount of viral load (VL) and 202 total symptom score (TSS) based on 10-symptom diary card, both evaluated during the window of 203 quarantine period. Further, where traditional meta-analysis was not possible, we used descriptive 204 statistics to provide overall estimates for some of the key time measures such as time to peak VL 205 and TSS. We compared these estimates with influenza and SARS-nCoV-2 since these are anti-viral 206 diseases that have approved treatments. Comparing the viral dynamics for RSV disease course to 207 other viral diseases, it appears that the time to mean peak VL is similar to SARS-nCoV-2 but occurs 208 much later compared to influenza. Moreover, comparing the symptom dynamics of these viral 209 diseases with RSV, peak TSS occurs later for SARS-nCoV-2, but early on for influenza. 210 Additionally, it appears that the mean time to reach the peak VL and the mean time to reach the peak TSS coincide for RSV. However, there is a delay of ~ 2 days for SARS-nCoV-2 and ~1 day 211 for influenza in reaching the peak TSS compared to peak VL. Additionally, we provided 95% 212 213 prediction interval for mean placebo VL AUC, mean placebo VL at peak and mean placebo TSS AUC in a new HCT and 95% reference interval for placebo VL AUC, placebo VL at peak and 214 215 placebo TSS AUC at an individual-level.

216

217 Generally, RSV challenge studies assess for RSV positivity from day 2 to day 5 post-inoculation prior to randomizing participants to study treatment. However, typically by day 5 it is assumed 218 219 that all participants may be RSV positive and are therefore randomized. The analysis for all the 220 efficacy endpoints in challenge studies is designed for RSV positive randomized patients, however, a small proportion of the subjects in the challenge studies may become positive after randomization 221 222 and therefore don't fully represent the clinical treatment situation. Imbalance in the viral load and 223 symptom severity, prior infection timing across the underlying populations from challenge studies and varying mechanism of action of drugs across the challenge studies could be a potential source 224 225 of heterogeneity, in addition to residual confounding due to unmeasured confounders.

226 Some of the potential limitations of our study can be attributed to the drawbacks of HCTs<sup>9</sup>. For 227 example, study sample size and number of studies are usually low due to ethical concerns and 228 safety risks. Available RSV HCT data evaluate treatment response in healthy adults with known 229 baseline RSV level seropositivity by controlled challenge strain that causes upper respiratory tract 230 infection limiting the evaluation of treatment response for lower respiratory tract infection. 231 Findings from challenge trials may not be directly applicable to the general population, as 232 participants are young, healthy, White and/or Caucasian adults, and their response to the pathogen 233 may differ from other demographic groups and those with co-morbidities or risk factors for severe 234 RSV disease. Results from challenge trials may be specific to the target population and the strain 235 of the pathogen used (the challenge virus in our review is RSV-A Memphis-37b), potentially 236 limiting the generalizability of the findings to other strains and other populations. Future studies 237 and research are needed to understand and assess the disease mechanisms for individuals in 238 placebo and treatment groups for other strains such as RSV-B and should include the ethnic/racial populations that are under-represented in the current HCTs, and the young and older individuals 239 240 with comorbidities that bare the greatest burden of disease. Other limitations of our study can be attributed to inconsistent availability of outcomes. For example, not all the study outcomes are 241 242 reported in all seven studies (only 4 studies report mean TSS AUC) restricting the power for those outcomes. Studies mostly reported time to mean peak VL/TSS instead of mean time to peak 243 244 VL/TSS which restricted us from performing the traditional meta-analysis. 245

Despite these limitations, our comprehensive assessment of the RSV HCTs provides detailed 246 247 understanding of the VL and symptom score kinetics that will enhance understanding of RSV 248 disease pathogenesis. Meta-analysis and descriptive statistics of the key measures allowed us to 249 evaluate the overall placebo group characteristics and relative reduction by combining information across studies, thus increasing the overall sample size, and addressing the limitation of low sample 250 251 size from a single HCT. Reference interval for some of the key measures will guide the clinician to determine if the patient's measurement lies within the normal range, and thus validating the 252 253 patient's inclusion in the HCT. Our study mainly focused on HCTs that used RSV-A Memphis-254 37b as the challenge virus in the experimental stage and therefore the results from our study are 255 applicable to RSV-A which is the most prevalent strain These results can be used to contextualize effects to other potential experimental drugs when tested on the same strain. Overall, findings from 256 257 our analysis can help researchers and clinicians in significantly accelerating the development of 258 RSV treatment interventions.

- 259
- 260

### 261 Methods:

262

# 263 Search Strategy/Study Eligibility

264

The search parameters for studies to be included in this meta-analysis were as follows; randomized controlled trials (RCT) that featured an intervention of a small molecule antiviral investigational product for the indication respiratory syncytial virus (RSV). These studies had to be conducted under the human viral challenge model, with healthy volunteers, and had to have a total number of inoculated participants greater than ten. Additionally, we only included studies that had viral load AUC as the primary endpoint and measured at least one of the following: peak viral load, time to peak viral load, peak total symptom score, total symptom score AUC, and time to peak

272 symptom score. The search was conducted using Biosis Previews, Embase, Ovid MEDLINE,

PubMed, ClinicalTrials.gov and EudraCT from data inception to August 2023. The search strategy
 we used was provided by a cross-functional team of researchers with expertise in conducting

systematic reviews and meta-analyses on RSV research (all authors).

276

## 277 Assessment of Risk of Bias

278

Bias from each of the studies are assessed independently by four reviewers based on Cochrane's
 domain-based criterion. The risk of bias is evaluated using the visualization tool robvis<sup>23</sup>.

## 282 Statistical Analysis

283

281

284 We considered seven different outcome measures, broadly classified into VL specific measures and symptom specific measures. VL specific measures included (1) mean placebo VL AUC where 285 286 the AUC is calculated from first dose until end of quarantine period (window length of ~12-13 days for the studies included), (2) relative reduction (RR) of mean VL AUC in treatment group 287 288 compared to placebo from the same study, (3) mean placebo VL at peak, (4) time (in days) to mean placebo peak VL. Symptom specific measures included (5) mean placebo TSS AUC where the 289 290 window length is similar to mean placebo VL AUC in (1), (6) RR of mean TSS AUC in treatment 291 group compared to placebo from the same study, and (7) time (in days) to mean placebo peak TSS. 292 Both the time variables (4) and (7) are measured from inoculation. We derived the estimate of RR, 293 (2) and (6) from the corresponding treatment and placebo estimates reported in the studies. For 294 deriving the time variables (4) and (7), we assumed a uniform distribution for the time (in days) 295 from RSV inoculation to first dose assignment, where the range varied from the day of inoculation 296 to the day of first dose assignment. This assumption is applicable for the studies which did not 297 report data on time variables (4) and (7) from inoculation but from assignment of first dose. In 298 studies that reported multiple doses for treatment regimens, we chose the cohort with the highest 299 dose for evaluating RR measures. Further, most (n=5) of the studies report the unit of VL AUC in 300 log10 PFUe.hr/mL (log10 PFUe.hr/mL = log (base 10) plaque-forming unit equivalents per 301 milliliter times hour), while some (n=2) report in log10 copies.hr/mL. For our analysis we assumed 302 equivalence between these units as confirmed as appropriate by the hVIVO. hVIVO is a contract 303 research organization specializing in infectious disease vaccines and therapeutics using human 304 challenge clinical trials<sup>24</sup>.

305

306 We constructed a database for each of the study outcome measures. The databases included the 307 corresponding outcome measure and associated SD for all the studies passing the 308 inclusion/exclusion criterion (see Figure 1). Details of evaluation of mean and SD from the literature is provided in Supplementary Methods. Frequentist random-effects model (using 309 restricted maximum likelihood estimation)<sup>25</sup> was implemented for each of the study outcomes 310 (except for time to mean peak VL and time to mean peak TSS) using the R package "meta"<sup>26</sup>, 311 312 where the constructed database associated with the respective study outcome served as an input 313 for the function "metamean" from the "meta" package. Forest plots were generated using the 314 function "forest.meta". We evaluate the prediction interval of a new study and reference interval for an individual recruited in HCT using the Rshiny app: RIMeta<sup>27</sup>. A 95% reference interval for a 315 316 particular measure is defined to be the interval in which we would expect 95% of the individual's 317 measurements from a future HCT to lie.

318

319 Most of the studies reported time to mean peak VL/TSS instead of mean time to peak VL/TSS. 320 Mean time to peak VL/TSS is assessed by first calculating the day of peak VL/TSS for each subject 321 and then taking the mean over days. In this case, each study would have provided a mean estimate over subjects and therefore would have fallen into the framework of traditional meta-analysis. 322 323 However, on the other hand, time to mean peak VL/TSS is assessed by first calculating the mean VL/TS curve over subjects at each day and then looking at the day where the peak is achieved. 324 325 Each study, therefore, provided a single observation for the time (in days) to peak VL/TSS. We 326 treated each study as a subject and used descriptive statistics (instead of traditional meta-analysis) 327 such as mean and median to provide overall estimates for time to mean peak VL/TSS accounting 328 for study-level uncertainty. 95% CI for median is calculated non-parametrically from quantiles<sup>28</sup>, 329 while for mean, we calculate it from Student's t-distribution. 330 331

- 332 Acknowledgement
- 333

We thank Dr. Haitao Chu, Senior Director and Statistics Lead at Pfizer Inc., for providinginsightful comments to the paper.

- 336 337
- 338
- 339 340

# 341 References:342

1. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*. May 28 2022;399(10340):2047-2064.

- 346 doi:10.1016/S0140-6736(22)00478-0
- Nguyen-Van-Tam JS, O'Leary M, Martin ET, et al. Burden of respiratory syncytial virus
   infection in older and high-risk adults: a systematic review and meta-analysis of the evidence
   from developed countries. *Eur Respir Rev.* Dec 31 2022;31(166)doi:10.1183/16000617.0105 2022

351 3. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus 352 infection in young children. *N Engl J Med*. Feb 5 2009;360(6):588-98.

353 doi:10.1056/NEJMoa0804877

Langley JM, Bianco V, Domachowske JB, et al. Incidence of Respiratory Syncytial Virus
 Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across
 Diverse Global Settings. J Infect Dis. Aug 26 2022;226(3):374-385. doi:10.1093/infdis/jiac227

McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of Medically
 Attended RSV Among US Adults: A Systematic Review and Meta-analysis. *Open Forum Infect Dis*.
 Jul 2022;9(7):ofac300. doi:10.1093/ofid/ofac300

360 6. McLaughlin JM, Khan F, Schmitt HJ, et al. Respiratory Syncytial Virus-Associated

361 Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. J Infect Dis.

362 Mar 15 2022;225(6):1100-1111. doi:10.1093/infdis/jiaa752

363 Zheng Z, Warren JL, Shapiro ED, Pitzer VE, Weinberger DM. Estimated incidence of 7. 364 respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups. 365 Pneumonia (Nathan). Oct 25 2022;14(1):6. doi:10.1186/s41479-022-00098-x 366 8. Darton TC, Blohmke CJ, Moorthy VS, et al. Design, recruitment, and microbiological 367 considerations in human challenge studies. Lancet Infect Dis. Jul 2015;15(7):840-51. 368 doi:10.1016/S1473-3099(15)00068-7 369 Valdés E. Human Challenge Trials in Pandemics: Risks and Benefits. In: Valdés E, Lecaros 9. 370 JA, eds. Handbook of Bioethical Decisions Volume I: Decisions at the Bench. Springer 371 International Publishing; 2023:373-384. 372 Cornell JE, Mulrow CD, Localio R, et al. Random-effects meta-analysis of inconsistent 10. 373 effects: a time for change. Ann Intern Med. Feb 18 2014:160(4):267-70. doi:10.7326/M13-2886 374 11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. Sep 375 1986;7(3):177-88. doi:10.1016/0197-2456(86)90046-2 376 12. Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-377 CoV-2 human challenge in young adults. Nat Med. May 2022;28(5):1031-1041. 378 doi:10.1038/s41591-022-01780-9 379 Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human 13. 380 influenza: a review of volunteer challenge studies. Am J Epidemiol. Apr 1 2008;167(7):775-85. 381 doi:10.1093/aje/kwm375 382 Bagga B, Woods CW, Veldman TH, et al. Comparing Influenza and Rsv Viral and Disease 14. Dynamics in Experimentally Infected Adults Predicts Clinical Effectiveness of Rsv Antivirals. 383 384 Antiviral Therapy. 2013;18(6):785-792. doi:10.3851/imp2629 385 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated 15. 386 guideline for reporting systematic reviews. BMJ. Mar 29 2021;372:n71. doi:10.1136/bmj.n71 387 16. Ahmad A, Eze K, Noulin N, et al. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a 388 Human Virus Challenge. N Engl J Med. Feb 17 2022;386(7):655-666. 389 doi:10.1056/NEJMoa2108903 390 DeVincenzo J, Cass L, Murray A, et al. Safety and Antiviral Effects of Nebulized PC786 in a 17. 391 Respiratory Syncytial Virus Challenge Study. J Infect Dis. Jun 15 2022;225(12):2087-2096. 392 doi:10.1093/infdis/jiaa716 393 DeVincenzo J, Tait D, Efthimiou J, et al. A Randomized, Placebo-Controlled, Respiratory 18. 394 Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of 395 RV521, an Inhibitor of the RSV-F Protein. Antimicrob Agents Chemother. Jan 27 396 2020;64(2)doi:10.1128/AAC.01884-19 397 19. DeVincenzo JP, McClure MW, Symons JA, et al. Activity of Oral ALS-008176 in a 398 Respiratory Syncytial Virus Challenge Study. N Engl J Med. Nov 19 2015;373(21):2048-58. 399 doi:10.1056/NEJMoa1413275 400 20. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory 401 syncytial virus challenge study. N Engl J Med. Aug 21 2014;371(8):711-22. 402 doi:10.1056/NEJMoa1401184 403 Stevens M, Rusch S, DeVincenzo J, et al. Antiviral Activity of Oral JNJ-53718678 in 21. 404 Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled 405 Study. J Infect Dis. Jul 24 2018;218(5):748-756. doi:10.1093/infdis/jiy227

22. Limited B. A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model. 23 Sep 2018. 2015-004296-77. Accessed 15 Aug 2023. https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004296-77/results 23. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods. 2020/04/26 2020;n/a(n/a)doi:10.1002/jrsm.1411 24. hVIVO. Accessed January, 30, 2024, 2024. https://hvivo.com Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance 25. estimators in simulated random-effects meta-analyses. Res Synth Methods. Mar 2019;10(1):83-98. doi:10.1002/jrsm.1316 Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical 26. tutorial. Evid Based Ment Health. Nov 2019;22(4):153-160. doi:10.1136/ebmental-2019-300117 27. Jiang Z, Cao W, Chu H, Bazerbachi F, Siegel L. RIMeta: An R shiny tool for estimating the reference interval from a meta-analysis. Res Synth Methods. May 2023;14(3):468-478. doi:10.1002/jrsm.1626 28. Conover WJ. Practical Nonparametric Statistics. vol 3rd Edition. Wiley; 1999:608. 

### 450 Figure 1: PRISMA Flow Diagram



451 452

453 Note: The meta-analysis is performed for 5 of the 7 study outcomes. Descriptive statistics is reported for the other 2
454 outcomes.



### 455 Figure 2: Forest plot for mean viral load area under the curve (VLAUC) in placebo.

Note: VL is assessed using RT-qPCR assay. Studies report the unit of VL in log10 copies/mL or log10 PFUe/mL, where log10PFUe/mL = log (base 10) plaque-forming unit equivalents per milliliter. In our analysis, we assumed a conversion factor of 1 across the units and is confirmed from hVIVO. Unit of VL AUC is log10 PFUe.hr/mL.

461 462 463

464

#### Figure 3: Forest plot for relative reduction (RR) of mean viral load area under the curve (VL 465 466 AUC) in treatment compared to placebo.

							Weight	Weight
Study	Drug	Dose	Ν	Mean	MRAW	95%-CI	(common)	(random)
DeVincenzo et al (2015)	ALS-008176	1 x 750 mg + 9 x 500 mg	20		0.88	[ 0.78; 0.98]	25.2%	15.4%
Biota Pharma Europe (2018)	BTA-C585	1 x 600 mg	25		0.01	[-0.19; 0.22]	5.9%	13.9%
Ahmad et al (2022)	EDP-938	5 x 600 mg QD	55		0.74	[ 0.64; 0.84]	26.3%	15.4%
DeVincenzo et al (2014)	GS-5806	1 x 50 mg + 4 x 25 mg QD	54		0.67	[ 0.57; 0.77]	26.5%	15.4%
Stevens et al (2018)	JNJ-53718678	7 x 500 mg QD	24		0.41	[ 0.10; 0.72]	2.6%	12.0%
DeVincenzo et al (2020) [1]	PC786	5 x 5 mg BID	34		0.34	[ 0.12; 0.57]	5.0%	13.6%
DeVincenzo et al (2020) [2]	RV521	5 x 350 mg BID	35		0.63	[ 0.46; 0.81]	8.4%	14.4%
Common effect model			247	\$	0.68	[ 0.63; 0.73]	100.0%	
Random effects model				0.54	[ 0.32; 0.76]		100.0%	
Heterogeneity: $I^2 = 91\%$ , $\chi_6^2 = 66$	8.28 (p < 0.01)		0 0.2 0.4 0.6 0.8					

Note: VL is assessed using RT-qPCR assay. Studies report the unit of VL in log10 copies/mL or log10 PFUe/mL, where log10 PFUe/mL = log (base 10) plaque-forming unit equivalents per milliliter. In our analysis, we assumed a conversion factor of 1 across the units and is confirmed from hVIVO. Unit of VL AUC is log10 PFUe.hr/mL.

472

### 473 Figure 4: Forest plot for mean viral load at peak in placebo.

						Weight	Weight
Study	Drug	N	Mean	MRAW	95%-CI	(common)	(random)
DeVincenzo et al (2015)	ALS-008176	12		5.30	[4.62; 5.98]	17.6%	16.1%
Biota Pharma Europe (2018)	BTA-C585	13		- 6.24	[5.41; 7.07]	11.8%	13.5%
Ahmad et al (2022)	EDP-938	30		5.40	[4.48; 6.32]	9.5%	12.1%
DeVincenzo et al (2014)	GS-5806	27		6.00	[5.41; 6.59]	23.4%	17.8%
Stevens et al (2018)	JNJ-53718678	12		4.70	[3.81; 5.59]	10.2%	12.5%
DeVincenzo et al (2020) [1]	PC786	15		5.00	[4.34; 5.66]	18.7%	16.5%
DeVincenzo et al (2020) [2]	RV521	19	*	4.77	[3.81; 5.73]	8.8%	11.5%
Common effect model		128		5.42	[5.14; 5.71]	100.0%	
Random effects model				5.38	[4.94; 5.81]		100.0%
Heterogeneity: $I^2 = 55\%$ , $\chi_6^2 = 1$	3.47 (p = 0.04)		4 4.5 5 5.5 6 6.5 7				

 $\begin{array}{r} 474\\ 475\\ 476\\ 477\\ 478\\ 480\\ 481\\ 482\\ 483\\ 485\\ 486\\ 487\\ 489\\ 491\\ 492\\ 493\\ 495\\ 496\\ 497\\ 499\\ 500\\ 502\\ \end{array}$ 

503

Note: VL is assessed using RT-qPCR assay. Studies report the unit of VL in log10 copies/mL or log10 PFUe/mL, where log10 PFUe/mL = log (base 10) plaque-forming unit equivalents per milliliter. In our analysis, we assumed a conversion factor of 1 across the units and is confirmed from hVIVO.

# 504 Figure 5. Forest plot for relative reduction (RR) of mean total symptom score area under the 505 curve (AUC) in treatment compared to placebo.

							weight	weight
Study	Drug	Dose	N	Mean	MRAW	95%-CI	(common)	(random)
DeVincenzo et al (2015)	ALS-008176 1	x 750 mg + 9 x 500 m	g 20		- 0.82	[ 0.67; 0.96]	32.5%	32.5%
Ahmad et al (2022)	EDP-938	5 x 600 mg QD	55		0.74	[ 0.61; 0.87]	43.3%	43.3%
DeVincenzo et al (2020) [1]	PC786	5 x 5 mg BID	41	+	0.29	[-0.25; 0.83]	2.3%	2.3%
DeVincenzo et al (2020) [2]	RV521	5 x 350 mg BID	35		- 0.78	[ 0.61; 0.96]	21.9%	21.9%
Common effect model			151	\$	0.76	[ 0.68; 0.85]	100.0%	
Random effects model				\$	0.76	[ 0.68; 0.85]		100.0%
Heterogeneity: $l^2 = 19\%$ , $\chi_3^2 =$	= 3.69 (p = 0.30)		-0.2 0	0.2 0.4 0.6 0.8				

Note: The total symptom score is evaluated based on 10 clinical symptoms from symptom dairy card. The reported AUC from each study is based on a window length of approximately 12-13 days.